• Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg invests in AlzeCure and is proposed for election to its board

  • AlzeCure publishes its interim report for January – March 2024

  • The extraordinary general meeting of AlzeCure Pharma AB approved the decision on the new issue of shares

AlzeCure Pharma

AlzeCure Pharma is a Swedish pharmaceutical company focusing on the research and development of innovative and efficacious treatments for Alzheimer’s disease and related disorders

Research

AlzeCure is developing disease modifying and symptomatic first in class treatments for Alzheimer’s disease and other conditions characterized by cognitive dysfunction

Alzheimer’s Disease

Alzheimer’s disease is a deadly disorder which lacks effective treatments. The need for novel treatments is therefore urgent.